Prof. Raffaele Mezzenga is a Full Professor at ETH Zürich's Department of Health Sciences and Technology and Head of the Institute of Food, Nutrition, and Health. He earned his master's from Perugia University (Italy) and a PhD in Polymer Physics from EPFL, followed by postdoctoral work at UC Santa Barbara. His career includes roles at the Nestlé Research Center and the University of Fribourg before joining ETH in 2009. His research focuses on self-assembly processes in polymers, biopolymers, and colloidal systems, with applications in environmental remediation, bioplastics, and biomedical materials. Key contributions include pioneering protein-based materials and advancing understanding of amyloid fibrils. Education: Master's, Materials Science & Engineering, Perugia University PhD, Polymer Physics, EPFL Research Interests: Self-assembly, biopolymers, amyloid materials, sustainable technologies, food colloids, and soft condensed matter. Awards: 2011 AOCS Award, 2017 APS Fellowship, and 2013 Biomacromolecules Young Investigator Award. Visiting Roles: Held visiting professorships at Aalto University, RMIT, Monash University, Nanyang Technological University, and others. Labs/Teams: Leads the Institute of Food, Nutrition, and Health at ETH, focusing on interdisciplinary research in food science and biomaterials. His work bridges fundamental science and applied innovation, addressing global challenges in sustainability and health through materials science. Recent projects include creating bioplastics from food waste, developing amyloid-based water purification systems, and advancing targeted drug delivery via lipidic mesophases.
Jennifer L. Clarke is a Professor in the Department of Statistics at the University of Nebraska–Lincoln and Director of the Quantitative Life Science Initiative. She holds leadership roles in enabling big data integration across the University of Nebraska system through collaborative research programs. Her affiliations include the Institute of Agriculture and Natural Resources (IANR) and the College of Agriculture and Natural Resources. Dr. Clarke's research focuses on statistical methodology for high-dimensional data, computational biology, bioinformatics, and bacterial genomics. Her work bridges statistical innovation with applications in oncology, microbiome analysis, and agricultural phenomics. Key areas include predictive modeling, machine learning, and genomic/metagenomic data integration. Her recent publications span cancer biomarker discovery, plant phenotyping methodologies, and microbial community analysis, reflecting her interdisciplinary approach. Articles emphasize translational applications like therapeutic target identification and precision agriculture. Dr. Clarke leads initiatives fostering collaboration between statisticians and domain scientists, including the Quantitative Life Science Initiative and contributions to the Agricultural Genome-to-Phenome Initiative (AG2PI). Her work advances data-driven solutions for healthcare and food security challenges. Notable projects include developing statistical tools for microbiome studies, analyzing root architecture via 3D imaging, and investigating cranberry-derived compounds' cancer-inhibitory mechanisms. Her methodological contributions include hybrid clustering techniques and predictive model validation frameworks.
Karan S Dixit, MD is an Assistant Professor in the Department of Neurology at Northwestern University's Feinberg School of Medicine, specializing in neuro-oncology and serving as Fellowship Director for the education program. His educational background includes: MD from Louisiana State University (2011) Internal Medicine Internship at University of Illinois at Chicago (2012) Neurology Residency and Chief Medical Resident at University of Illinois at Chicago (2015) Neuro-Oncology Fellowship at Northwestern University McGaw Medical Center (2016) He maintains board certification in Neurology (American Board of Psychiatry and Neurology) and Neuro-Oncology (United Council for Neurologic Subspecialties). Dr. Dixit's research centers on CNS lymphoma, lower-grade gliomas, and glioblastoma, with emphasis on novel therapies for treatment resistance. He investigates biomarkers for disease monitoring and explores neurocognitive decline mechanisms related to neural connectivity changes during CNS cancer treatment. His work bridges clinical neurology with translational oncology through molecular diagnostics and therapeutic innovation. His 2025 publications reveal three critical research trajectories: molecular characterization of glioma mutations (TERT/IDH), liquid biopsy applications for CNS lymphoma diagnosis, and repurposing antiseizure drugs with antineoplastic potential. These studies collectively advance precision medicine approaches for treatment-resistant CNS malignancies. Professional recognition includes: John A Kessler Teaching Award (2022, 2019) NeuroNEXT Fellow (2020) Society of Neuro-Oncology Clinical Trials Course (2019) University of Illinois Teaching Excellence Awards (2014-2015) As Fellowship Director, Dr. Dixit mentors neuro-oncology trainees while leading three active clinical trials: Vorasidenib/Pembrolizumab for IDH-mutant glioma (NCT05484622), NX-5948 BTK degrader for CNS lymphoma (NCT05131022), and emavusertib for relapsed PCNSL (NCT03328078). His industry collaborations include Bluprint Oncology Concepts and Servier Pharmaceuticals for therapeutic development. He maintains active membership in the Feinberg Academy of Medical Educators, American Neurological Association, American Academy of Neurology (Neuro-Oncology Section), American Society of Clinical Oncology, and Society of Neuro-Oncology, collaborating through Northwestern Medicine's Robert H. Lurie Comprehensive Cancer Center and Clinical and Translational Sciences Institute.
Dr. Nhiem Tran is a Senior Lecturer in the Department of Applied Chemistry and Environmental Science at RMIT University's School of Science, part of the STEM College. He joined RMIT in 2015 as a Vice Chancellor's Research Fellow after completing his PhD in Physics at Brown University (USA, 2012) and postdoctoral research at Rhode Island Hospital (USA), CSIRO, and the Australian Synchrotron. His research focuses on developing biomaterials for drug delivery, gene therapy, and medical implants, particularly lipid nanoparticles and 3D-printed metallic implants. He leads the Biomaterial Interfaces group, investigating self-assembled lipid nanoparticles for cancer and autoimmune disease treatments. His work has resulted in over 65 high-impact publications and numerous awards, including the RMIT Vice Chancellor's Research Fellowship and the Stein/Bellet Foundation Fellowship. Tran's funding comes from grants such as the ARC Discovery Project, mRNA Victoria, and the CASS Foundation. His research interests span nanomedicine, biomedical engineering, and materials science, with a focus on applications in drug delivery, bacterial infection control, and orthopaedic implants. Education: PhD in Physics (Brown University, 2012) Key Projects: 3D-printed diamond-titanium implants, lipid nanoparticle drug carriers, and antimicrobial coatings. He actively supervises postgraduate research in areas like nanomaterials for drug delivery and biomedical applications.
Professor Guy Williams is a leading academic at the University of Cambridge with a focus on imaging science and clinical neurosciences, affiliated with Downing College and the Wolfson Brain Imaging Centre . Holding a PhD in Physics from his initial Natural Sciences degree, he specializes in nuclear magnetic resonance (NMR) and MRI techniques for brain imaging. Education: BA, PhD in Physics His research centers on non-invasive imaging of brain structure and function, particularly in traumatic brain injury (TBI) and dementia. His work involves developing novel MRI pulse sequences and advanced data analysis algorithms, including AI-based diagnostic tools. He leads studies on white matter integrity post-trauma, longitudinal dementia assessment, and applications of MRI in disorders of consciousness and addiction. Recent publications highlight collaborations in traumatic brain injury outcomes, AI-guided dementia prediction, and neuroimaging of post-COVID cognitive deficits. His team's work on ultra-high field laminar fMRI and distortion correction methods has advanced clinical neuroscience applications. Key techniques include diffusion tensor imaging (DTI), 7 Tesla MRI, and positron emission tomography (PET/MR). His research spans from basic NMR physics to clinical translation, with a strong emphasis on multi-site studies and real-world diagnostic implementation.
Karl Griswold is a Professor of Engineering at Dartmouth College's Thayer School of Engineering, where he leads the Griswold Research Group focused on protein engineering and biotherapeutics development. His interdisciplinary work spans chemical, biological, and engineering disciplines to address critical challenges in drug-resistant infections and protein therapeutics. Education: BS in Chemistry from Southwest Texas State University (1995) PhD in Chemistry from the University of Texas at Austin (2005) Research Focus: Professor Griswold's laboratory specializes in protein engineering, directed evolution, and biotherapeutics development , creating novel biomolecules with superior functionality compared to natural proteins. The group develops high-throughput screening methods, protein deimmunization strategies, enhanced expression systems, and antibacterial agents targeting drug-resistant infections. Their work has significant translational potential for treating conditions like MRSA and Pseudomonas aeruginosa infections. Scientific Recognition: Wallace H. Coulter Foundation Early Career Translational Research Award in Biomedical Engineering (2008) NIH Biotechnology Training Grant (2000-2003) Royston M. Roberts - Regents Fellowship, University of Texas (1999) DOW Chemical Foundation Scholar, Texas State University (1991-1995) Senior Fellow, National Academy of Inventors Research Leadership: As co-founder and CEO of Stealth Biologics, Professor Griswold translates academic research into commercial applications. His work has secured NIH funding and Dartmouth Innovations Accelerator support, with research featured in Chemical & Engineering News, Vermont Public Radio, and the New Hampshire Union Leader for developing alternatives to traditional antibiotics. Research Environment: The Griswold Research Group maintains extensive collaborations across disciplines including clinical medicine, immunology, structural biology, and chemical engineering. This interdisciplinary approach prepares trainees for careers at the intersection of multiple scientific fields, with research focusing on Biomolecular Antimicrobial Therapies, Deimmunizing Protein Therapeutics, and Gene Library Construction Technologies.
Professor Hala Zreiqat AM is a leading biomedical engineer at The University of Sydney , serving as the Director of the ARC Training Centre for Innovative BioEngineering . A Fellow of all major Australian academies (AAS, ATSE, FAHMS, FRSN), she develops 3D printed bioceramics for bone regeneration while championing diversity through initiatives like the IDEAL Society and BIOTech Futures mentorship program. Her work bridges academia, clinical practice, and industry in musculoskeletal research . Research Focus: Her lab creates synthetic bone scaffolds that mimic natural bone architecture, strength, and porosity, enabling non-rejected bone regeneration via patient-matched implants. Key applications include orthopaedic, dental, and maxillofacial repair , with over $18M in competitive funding and multiple patents. Current projects explore AI-driven scaffold performance prediction and anti-senescence strategies for aging-related bone loss. Scientific Trends: Recent publications highlight 3D printed nanovoxelated ceramics , antisenescence biomaterials , and multifunctional theranostic platforms . Her team integrates machine learning for scaffold design, atom probe tomography for interface analysis, and two-photon imaging for cellular monitoring in 3D environments. 2021-2022 Fulbright Senior Scholar 2018 NSW Premier's Woman of the Year 2019 Eureka Prize for Innovative Use of Technology Fellow of Australian Academy of Science (2021) Over $18M in research funding Teaching & Leadership: She designed core courses like Tissue Engineering and Nanomaterials in Medicine , mentoring 158 students in 2020 alone. As Chair of CAAR (2020-2023), she strengthens Australia-Arab collaborations. Her lab trains early-career researchers , with alumni now in academia and industry.
Sunitha Nagrath is a Professor of Chemical Engineering at the University of Michigan, leading the Nagrath Lab. Her research focuses on developing microfluidic and nanotechnology-based tools to isolate and analyze circulating tumor cells (CTCs) and extracellular vesicles (EVs) for cancer diagnostics and personalized medicine. She holds an AIMBE Fellowship and has pioneered technologies like the Graphene Oxide Chip and Microfluidic Labyrinth. Education PhD in Mechanical Engineering, Rensselaer Polytechnic Institute (2004) MS in Nuclear Engineering, Rensselaer Polytechnic Institute (2000) B.Tech in Chemical Engineering, Sri Venkateswara University (1992) Research Interests Her lab integrates engineering, biology, and clinical expertise to study CTCs' role in metastasis, develop high-throughput isolation methods, and leverage exosomes as liquid biopsy biomarkers. Key projects include: CTC-based monitoring of therapy response in lung and pancreatic cancers Microfluidic devices for simultaneous CTC and exosome analysis Functional studies of CTC-derived organoids for drug sensitivity testing Notable Achievements AIMBE Fellow (Junior Faculty, Harvard Medical School/MGH, 2008-2010) Over 150 peer-reviewed publications and patents on CTC/exosome technologies Recipient of the 2021-22 Chemical Engineering Staff Incentive Award (via lab member Mina Zeinali) Labs & Collaborations The Nagrath Lab collaborates with clinicians and engineers to translate technologies like the OncoBean Chip and EVOD chip into clinical settings. Current work emphasizes real-time CTC monitoring and exosome-based immuno-oncology strategies.
Dr. Hongtu Zhu is the Kenan Distinguished Professor of Biostatistics, Statistics, Radiology, Computer Science, and Genetics at the University of North Carolina at Chapel Hill (UNC). He holds affiliations with the Gillings School of Global Public Health and leads the Biostatistics and Imaging Genomics Analysis Lab. His expertise spans statistical learning, medical imaging, AI, and big data integration, with a focus on precision medicine and biomedicine. Dr. Zhu earned his PhD in Statistics from The Chinese University of Hong Kong (2000) and has held prior roles including DiDi Fellow/Chief Scientist (2018-2020) and Bao-Shan Jing Endowed Professor at MD Anderson Cancer Center (2016-2018). He has published over 345 peer-reviewed articles in top-tier journals like Nature, Science, and JASA, and actively contributes to editorial roles including Coordinating Editor of JASA. His research interests include neuroimaging analysis, knowledge graphs, and AI applications in healthcare. Notable awards include the COPSS Snedecor Award (2025), IEEE Fellowship (2025), and IMS Medallion (2027). He has mentored over 80 PhD students/postdoctoral fellows and serves on NIH grant review panels and professional organizations like the ASA's Section on Statistics in Imaging. Key Contributions: Imaging genomics, brain connectivity studies, ridesharing market optimization, medical AI frameworks Lab Innovations: Brain Imaging Genetics Knowledge Portal, Biomedical Knowledge Graph Interface Teaching: Advanced biostatistics courses (Generalized Linear Models, Deep Learning in Biomedicine) Recent work explores causal inference in healthcare, X chromosome's role in neurobiology, and AI ethics in medical vision-language models. His interdisciplinary projects bridge statistics, computer science, and clinical practice to address complex biomedical challenges.
JIANG Xingyu is Chair Professor and Head of the Department of Biomedical Engineering at the Southern University of Science and Technology (SUSTech) . Since 2018 he has led a multidisciplinary team developing advanced micro- and nano-scale tools for analytical chemistry, microfluidics and nanomedicine. Education Postdoctoral Research, Harvard University (2004–2005) Ph.D. in Chemistry, Harvard University (2004) B.S. in Chemistry, University of Chicago (1999) Research Interests Professor Jiang’s research integrates analytical chemistry , microfluidics , biomedical engineering and nanomedicine . His laboratory designs microfluidic chips for point-of-care diagnostics, engineers gold nanoclusters and nanoparticles for antimicrobial and anticancer therapy, and develops soft flexible bio-electronics for neural interfaces and wearable health monitoring. Across 400+ publications, recent work demonstrates a clear trend toward translational nanomedicine : point-of-care viral variant detection, nanoantibiotic strategies against multidrug-resistant bacteria, CRISPR delivery systems for cancer therapy, and conformal electronic tattoos for human-machine interfaces. Scientific Awards & Honours Fellow, American Institute for Medical and Biological Engineering (2020) Fellow, Royal Society of Chemistry (2016) Tencent Science Exploration Award (2019) Chief Scientist, National Key R&D Program (2019–) National Science Fund for Distinguished Young Scholars (2010) Young Investigator Award, Human Frontier Science Program (2007) Research Funding & Teams He currently directs the Nanoscience Laboratory at SUSTech, hosts National Key R&D Program projects as Chief Scientist, and serves on editorial boards of Advanced Healthcare Materials , Lab on a Chip , Nanoscale Horizons , Nanoscale and Nanoscale Advances . The group is actively recruiting post-docs, research professors and technicians across chemistry, materials, biology and medical engineering disciplines.
Christian Friedrich Wilhelm Becker is a full Professor at the University of Vienna, holding a position within the Faculty of Chemistry and the Department of Biological Chemistry. His research profile shows extensive activity in protein chemistry and biochemistry, with particular focus on post-translational modifications and their implications in disease mechanisms. His work bridges chemical biology, biochemistry, and biomedical applications, contributing significantly to the academic and research landscape at one of Europe's oldest and most prestigious universities. Faculty of Chemistry, University of Vienna Department of Biological Chemistry Active research leader with numerous ongoing projects Significant publication record spanning multiple disciplines Professor Becker's research primarily focuses on protein chemistry, particularly post-translational modifications and their role in protein function and dysfunction. His work spans multiple interconnected areas including ubiquitination, protein aggregation, prion protein behavior, and biomimetic approaches to protein analysis. His research has significant implications for understanding neurodegenerative diseases and developing novel therapeutic approaches. The fingerprint analysis of his work shows strong connections to biochemistry, molecular biology, and chemistry, with particular emphasis on cysteine chemistry, glycosylation, and amino acid modifications. Analysis of Professor Becker's recent publications (2021-2025) reveals a consistent research trajectory focused on protein modification techniques and their biological implications. His work shows increasing sophistication in chemical biology approaches to study protein function, with particular emphasis on ubiquitination pathways and protein aggregation mechanisms. The integration of chemical synthesis methods with biological analysis represents a hallmark of his research approach. His publications span high-impact journals in biochemistry, chemical biology, and peptide science, demonstrating the interdisciplinary nature of his contributions. Professor Becker has received notable recognition for his research contributions, most prominently the Cathay Award in 2020. This award acknowledges his significant contributions to the field of protein chemistry and chemical biology. His work appears to have practical applications in therapeutic development, particularly in the areas of targeted protein degradation and immunotherapy, which likely contributed to this recognition. Cathay Award (2020) Professor Becker leads multiple significant research projects, including 'Targeted protein degradation - from small molecules to complex organelles' (2020-2024), 'Taktira: Development of an improved, low-side-effect and sustainable immunotherapy' (2019-2023), and 'Structure Zoom: Zooming in on protein functional sites with atomic resolution' (2018-2021). These projects demonstrate substantial grant funding and collaborative research efforts across multiple institutions. His active participation in 290 recorded activities through 2025 indicates a highly engaged research program with numerous collaborators and trainees. Targeted protein degradation project (2020-2024) Taktira immunotherapy project (2019-2023) Structure Zoom project (2018-2021) Professor Becker's research environment includes a robust team of collaborators and junior researchers, as evidenced by the numerous co-authored publications and activities. His work intersects with multiple research groups studying protein function, modification, and therapeutic applications. The international collaboration network shown in his profile indicates significant engagement with researchers across multiple countries, creating a dynamic research ecosystem focused on advancing protein science and its biomedical applications.
Dr. Yi Shen is a Senior Lecturer at the School of Chemical and Biomolecular Engineering, The University of Sydney, and Chair of RACI Women in Chemistry. She is also affiliated with multiple research institutes including Sydney Institute of Agriculture, Sydney Southeast Asia Centre, The Centre for Drug Discovery Innovation, and The University of Sydney Nano Institute. PhD in Soft Materials from ETH Zurich Postdoctoral research at University of Cambridge and Harvard University Her research focuses on protein phase behavior and functional biomaterials development, utilizing soft matter approaches and microfluidic techniques to address challenges in neurodegenerative diseases, sustainable materials, and biomedical engineering. She has published extensively in top journals like Nature Nanotechnology and PNAS, with a particular emphasis on: Protein liquid-liquid phase separation mechanisms Biomaterials from protein nanofibrils Microfluidic manipulation of biological systems Biodegradable bioplastics development Shear force effects on biomolecular systems Pathological protein aggregation dynamics Key scientific achievements include: 2022 ARC DECRA Fellowship 2022 Sydney Nano Frontier award 2018 ETH Zurich Spark Award (for Fe delivery system invention) 2012 Princeton Grand Challenges Program 2 patents pending 2 Nature Nanotechnology cover articles As an educator, she coordinates CHNG2802 Chemical Engineering Modelling and Analysis, co-teaches CHNG3804 Biochemical Engineering and CHNG5605 Bio-products: Laboratory to Marketplace, and guest lectures across biomedical and nanotechnology programs. Her lab actively collaborates with institutions in Switzerland (ETH Zurich), UK (Cambridge), and US (Harvard, Princeton), focusing on transforming biomolecular understanding into real-world applications in health, industry, and environmental sustainability.
Dr. Daniel Roxbury is an Associate Professor and Graduate Director at the Department of Chemical, Biomolecular and Materials Engineering within the University of Rhode Island's College of Engineering. With expertise in nanoscience and carbon nanomaterials, his research focuses on nano-bio interactions, developing functionalized nanotubes for biomedical applications and environmental monitoring through his NanoBio Engineering Laboratory. His work spans multiple disciplines including: Biomedical nanosensors Smart wearable biomaterials Targeted drug delivery systems Environmental nanotechnology Single-molecule imaging Nanotoxicology Recent publications emphasize machine learning-enhanced spectral analysis, coral reef conservation nanotechnology, and wearable stress monitoring textiles. His 2024 ACS Nano study introduces AI-driven macrophage phenotyping, while 2023 Nature Nanotechnology work explores coral reef restoration strategies using nanomaterials. Awarded the 2019 NSF CAREER grant for cellular nanometrology, he leads multiple NIH-funded projects including: $820,000 NSF CAREER: Spectral Imaging for Sub-Cellular Nanometrology $140,000 Miriam Hospital COBRE: Cortisol Detection Textiles $700,000 NSF EAGER: Multiplexed Wound Biomarker Detection His laboratory houses state-of-the-art equipment including: Near Infrared Hyperspectral Microscope Custom NIR Fluorescence Spectrometer Jasco UV/VIS/NIR Spectrophotometer Biosafety Cabinet Cell Culture Incubator Cryo-Storage System
Aditi Das is a Full Professor in the School of Chemistry and Biochemistry at the Georgia Institute of Technology, College of Sciences. She leads the Das Laboratory, which focuses on the biochemistry and chemical biology of lipids, particularly studying cytochrome P450 enzymes and their role in lipid metabolism, endocannabinoid systems, and inflammatory pathways. Her educational background includes: B.Sc. in Chemistry from St. Stephen's College M.Sc. in Chemistry from Indian Institute of Technology, Kanpur (I.I.T) Ph.D. in Chemistry from Princeton University Postdoctoral research at Northwestern University (NSF-NSEC fellow) and Beckman Institute for Advanced Science and Technology, University of Illinois UC Professor Das's research interests center around understanding the physiological role of lipids in sustaining homeostasis and their implications in disease states such as neurodegenerative disorders, cancer, and cardiovascular diseases. Her laboratory specializes in: Enzymology of cytochrome P450s, particularly CYP2J2 epoxygenase Metabolism of ω-3 and ω-6 fatty acids and their derivatives Minor cannabinoid metabolism by cytochrome P450 enzymes Discovery of novel anti-inflammatory lipid metabolites and endocannabinoids Mechanistic studies of membrane proteins using nanodisc technology Her work bridges biochemistry, chemical biology, and pharmacology to uncover novel therapeutic targets related to lipid signaling pathways. Analysis of Professor Das's recent publications (2023-2025) reveals a strong focus on cannabinoid metabolism by cytochrome P450 enzymes, with particular emphasis on how these metabolic processes generate bioactive compounds that interact with the endocannabinoid system. Her research increasingly explores the therapeutic potential of omega-3 derived endocannabinoid epoxides in inflammatory and neurodegenerative conditions. The use of nanodisc technology for studying membrane proteins in near-native environments remains a consistent methodological thread throughout her work, enabling detailed mechanistic insights into enzyme function. Professor Das has received numerous prestigious awards recognizing her research excellence and teaching: 2024 NIH Outstanding Researcher Award (MIRA R35) for established investigators 2024 Vasser Woolley Faculty Fellowship 2023 Plenary Lecture at the International Society of the Study of Xenobiotics (ISSX) 2021 E.L.R. Stokstad Award 2019-2021 List of Teachers Ranked as Excellent 2019 Eicosanoid Research Foundation Young Investigator Award 2019 Zoetis Research Excellence Award 2019 Mary Swartz Rose Young Investigator Award 2015 National Scientist Development Award from the American Heart Association 2022 El Sohly Award from the American Chemical Society Professor Das actively mentors a diverse group of students and postdoctoral researchers, with several former lab members now holding faculty positions or working at prestigious institutions. Her laboratory has secured significant funding from NIH, NSF, and other sources to support research on lipid metabolism, cannabinoid pharmacology, and membrane protein biochemistry. Notable grants include an NIH R35 Outstanding Investigator Award (MIRA), an NIH R21 grant from NIDA, and multiple collaborative grants with other research groups. The Das Laboratory operates within the Petit Institute of Bioengineering and Biosciences (IBB) at Georgia Tech, utilizing state-of-the-art facilities for biochemical and biophysical studies. The lab specializes in nanodisc technology to study membrane proteins in near-native environments, with particular expertise in cytochrome P450 enzymes and their interactions with lipid substrates. Recent work has expanded into collaborative projects involving lipidomics, structural biology, and translational applications of lipid signaling research.
Mona Singh is a Professor of Computer Science at Princeton University, with affiliations to the Lewis-Sigler Institute for Integrative Genomics and the Department of Molecular Biology. She has been a faculty member since 1999. Ph.D., Massachusetts Institute of Technology, 1995 A.B. and S.M. degrees in Computer Science from Harvard University Her research focuses on computational molecular biology, integrating machine learning and algorithms to analyze biological networks, protein interactions, and mutational impacts. Key areas include DNA/RNA binding prediction, protein structure analysis, and network-based disease gene discovery. Her recent work highlights trends in protein language models, kinase-substrate prediction, and equitable MHC binding algorithms. These span sub-fields like structural bioinformatics, network biology, and functional genomics. Scientific Awards: Presidential Early Career Award for Scientists and Engineers (PECASE) Rheinstein Junior Faculty Award ACM Fellow (2019) ISCB Fellow (2018) She has taught an introductory computational biology course with Professor Coleen Murphy, covering sequence analysis, phylogenetics, and network reconstruction. Her group has developed tools like dPUC , nCOP , and DiffMut . Her lab collaborates with institutions including Carnegie Mellon, Duke University, and the Broad Institute, advancing applications in cancer genomics, metabolic disease, and precision medicine.
